Patents Assigned to VIROCURE, INC.
  • NOVEL MODIFIED REOVIRUS AND USE THEREOF
    Publication number: 20240041959
    Abstract: Provided is a modified reovirus, a pharmaceutical composition thereof, and a method of treating cancer using the same which not only has an excellent anticancer effect on various cancers, including rare cancers, but can also enhance the effect of cancer immunotherapy agents.
    Type: Application
    Filed: December 22, 2021
    Publication date: February 8, 2024
    Applicant: VIROCURE, INC.
    Inventors: Haeng Jun YOO, Sang Kyoung HAN, Yeon Sook LEE, Ki Hoon SONG
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SQUIRREL FIBROMA VIRUS AND REOVIRUS
    Publication number: 20240024393
    Abstract: The present invention relates to a use of squirrel fibroma virus and a reovirus for preventing or treating cancer. A pharmaceutical composition comprising the squirrel fibroma virus and the reovirus, or a biological sample treated with the two viruses according to the present invention does not affect human normal cells but exhibits oncolytic activity by specifically infecting cancer cells, resulting in the inhibition of cancer cell growth.
    Type: Application
    Filed: January 22, 2020
    Publication date: January 25, 2024
    Applicant: VIROCURE, INC.
    Inventors: Man-Bok KIM (deceased), Jin Ah CHO, Ki-Hoon SONG
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER
    Publication number: 20230241141
    Abstract: Provided are a pharmaceutical composition including reovirus or reovirus-treated biological sample as an active ingredient for prevention or treatment of cancer, and a method for prevention or treatment of cancer using same. In addition, provided are a combination use of the pharmaceutical composition and an immune checkpoint inhibitor for treatment of cancer.
    Type: Application
    Filed: April 7, 2021
    Publication date: August 3, 2023
    Applicant: VIROCURE, INC.
    Inventors: Haeng Jun YOO, Sang Kyoung HAN, Yeon Sook LEE, Chan KIM, Hong Jae JEON
  • COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OF DIGESTIVE SYSTEM OR COLITIS, COMPRISING REOVIRUS AS ACTIVE INGREDIENT
    Publication number: 20230165916
    Abstract: The present disclosure relates to a composition for preventing, alleviating, or treating an inflammatory disease of the digestive system, particularly, colitis, comprising a reovirus or a variant thereof as an active ingredient.
    Type: Application
    Filed: January 29, 2021
    Publication date: June 1, 2023
    Applicant: VIROCURE, INC.
    Inventors: Yeon Sook LEE, Haeng Jun YOO, Sang Kyoung HAN
  • COMBINED USE OF SQUIRREL POXVIRUS AND MYXOMA POXVIRUS, FOR TREATING CANCER
    Publication number: 20210169957
    Abstract: Provided is a composition and method for treating cancer in a patient in need of cancer treatment, and the cancer can be treated by a combined therapeutic use of squirrel poxvirus and myxoma poxvirus.
    Type: Application
    Filed: July 30, 2019
    Publication date: June 10, 2021
    Applicant: VIROCURE, INC.
    Inventor: Manbok KIM (deceased)
  • Attenuated reovirus
    Patent number: 10668119
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 2, 2020
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • Attenuated reoviruses for selection of cell populations
    Patent number: 10369171
    Abstract: The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: August 6, 2019
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Derrick E. Rancourt, Nicole Zur Nieden, Randal N. Johnston
  • Attenuated reovirus
    Patent number: 10260049
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid ?1 protein and expresses a mutated reoviral outer capsid ?3 protein.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: April 16, 2019
    Assignee: VIROCURE, INC.
    Inventors: Manbok Kim, Randal N. Johnston
  • ATTENUATED REOVIRUS
    Publication number: 20170049829
    Abstract: Compositions and methods are provided that relate to an attenuated reovirus exhibiting oncolytic activity toward cancer cells while displaying reduced lytic activity toward non-malignant cells. Exemplified is an attenuated human reovirus derived from persistently infected fibrosarcoma cells that lacks wild-type reovirus S1 and S4 genes and consequently lacks a detectable reoviral outer capsid .sigma.1 protein and expresses a mutated reoviral outer capsid .sigma.3 protein.
    Type: Application
    Filed: August 24, 2016
    Publication date: February 23, 2017
    Applicant: VIROCURE, INC.
    Inventors: Manbok KIM, Randal N. Johnston